Indeed, the combination of ICI with MET inhibitors, mTOR inhibitors, or BCL2 inhibitors has demonstrated efficacy in several cancer types other than GC.28, 29, 31, 40, 41, 42, 43. Here, BCL2 is linked to cancer.